NCT02818582 - GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions

Ebola

Interventions

DRUG

GS-5734

Daily GS-5734 delivered intravenously (IV) for 5 days

OTHER

Placebo Comparator

Placebo delivered intravenously (IV) for 5 days.

Trial Locations (2)

Partnership of Clinical Research in Guinea (PREGUI) / Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Forécariah

JFK Hospital Partnership for Research for Vaccines and Infectious Diseases in Liberia (PREVAIL), Monrovia